{
    "clinical_study": {
        "@rank": "85725", 
        "arm_group": {
            "arm_group_label": "Text message monitoring", 
            "arm_group_type": "Other", 
            "description": "Use of text messaging to monitor post-vaccination"
        }, 
        "brief_summary": {
            "textblock": "In this study, the investigators will prospectively assess fever rates and other adverse\n      events in pregnant women after administration of inactivated influenza vaccine (IIV) using\n      text messaging. The investigators hypothesize that women <20 weeks gestational age who\n      receive IIV will be willing to enroll in a text messaging-based vaccine adverse event\n      monitoring program and will use it to report fever in the post-vaccination period as well as\n      continue to text pregnancy-related outcomes through the end of their pregnancy."
        }, 
        "brief_title": "PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pregnancy", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Are pregnant with a gestational age of <20 weeks either by last menstrual period\n             (LMP) and/or ultrasound\n\n          2. Are at least 18 years of age\n\n          3. Have a visit at a study site during the enrollment period\n\n          4. Receive IIV at that visit\n\n          5. Have a cell phone with text messaging capabilities\n\n          6. Are English or Spanish-speaking\n\n          7. Are willing to report via text message through end of pregnancy\n\n        Exclusion Criteria:\n\n          1. Decision to not continue with pregnancy\n\n          2. Any contraindication to receipt of inactivated influenza vaccines\n\n          3. Receipt LAIV (live attenuated influenza vaccine) at that visit\n\n          4. Previous receipt of IIV in this pregnancy\n\n          5. Presence of fever >=100.4F at time of vaccination;\n\n          6. Administration of any antipyretic in the 6-hour period prior to vaccination,\n\n          7. Stated intent, at time of vaccination, to use prophylactic antipyretics before the\n             development of a fever;\n\n          8. Patient only speaks a language other than English or Spanish\n\n          9. Patient does not have a cell phone with text messaging\n\n         10. Patient's inability to read text messages"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "165", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974050", 
            "org_study_id": "AAAM4906"
        }, 
        "intervention": {
            "arm_group_label": "Text message monitoring", 
            "intervention_name": "Text message surveillance", 
            "intervention_type": "Behavioral"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Influenza vaccination", 
        "lastchanged_date": "March 16, 2014", 
        "location": {
            "contact": {
                "email": "mss2112@columbia.edu", 
                "last_name": "Melissa Stockwell, MD MPH", 
                "phone": "212-342-5732"
            }, 
            "facility": {
                "address": {
                    "city": "NY", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10032"
                }, 
                "name": "Columbia University"
            }, 
            "investigator": [
                {
                    "last_name": "Melissa Stockwell, MD MPH", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Philip LaRussa, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Paula Castano, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Cynthia Gyamfi Bannerman, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "PregText: Assessing the Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging", 
        "other_outcome": [
            {
                "description": "Fever days 0 to 2 post-vaccination", 
                "measure": "Fever", 
                "safety_issue": "No", 
                "time_frame": "2 days"
            }, 
            {
                "description": "Problems reported during pregnancy", 
                "measure": "Pregnancy complication", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Pregnancy outcome including termination, preterm birth, term birth or stillbirth", 
                "measure": "Pregnancy outcome", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }
        ], 
        "overall_contact": {
            "email": "mss2112@columbia.edu", 
            "last_name": "Melissa Stockwell, MD MPH", 
            "phone": "212-342-5732"
        }, 
        "overall_official": [
            {
                "affiliation": "Columbia University", 
                "last_name": "Melissa Stockwell, MD MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Columbia University", 
                "last_name": "Philip LaRussa, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centers for Disease Control and Prevention", 
                "last_name": "Maria Cano, MD MPH", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "% of pregnant women <20 weeks gestational age who receive IIV who will be willing to enroll in a text messaging-based vaccine adverse event monitoring program", 
            "measure": "Feasibility of recruiting pregnant women <20 weeks gestational age", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974050"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Columbia University", 
            "investigator_full_name": "Melissa Stockwell, MD, MPH", 
            "investigator_title": "Assistant Professor of Pediatrics and Population and Family Health", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "% of women enrollees who text temperature-related information for the d0-2 period post-vaccination", 
                "measure": "Feasibility of text messaging to assess fever frequency in the d0-2 post-vaccination with IIV", 
                "safety_issue": "No", 
                "time_frame": "on vaccination day and the next 2 days (D0-2)"
            }, 
            {
                "description": "% of women enrollees who continue to text pregnancy-related outcomes through the end of their pregnancy", 
                "measure": "Feasibility of text messaging to monitor pregnancy outcomes through the end of pregnancy", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }
        ], 
        "source": "Columbia University", 
        "sponsors": {
            "collaborator": {
                "agency": "Centers for Disease Control and Prevention", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Columbia University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}